Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy

• Status: Enrolling by invitation
• Trial end date: 2022-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This pilot study is to determine whether it would be safe and feasible to inject CD34+ stem cells from bone marrow into the eye as treatment for patients who are irreversibly blind from various retinal conditions.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, Davis

Criteria

Inclusion Criteria:

• age >18 years of age

• visual acuity 20/100 to CF

• duration of vision loss > 3 months

• vision loss from macular degeneration, retinitis pigmentosa, retinal vein occlusion or diabetic retinopathy

• the study eye has the worse visual acuity

• no active eye or systemic disease

• no history of macular edema or retinal/choroidal neovascularization requiring treatment within 6 months

• no significant media opacity

• no coagulopathy or other hematologic abnormality

• no concurrent immunosuppressive therapy

• able to keep follow-up for 6 months

Exclusion Criteria:

• allergy to fluorescein dye

• other concurrent retinal or optic nerve disease affecting vision